TheraRadar
Data updated: May 26, 2026

FARYDAK (panobinostat lactate)

Oncology Approved 2015-02-23
1
Indication
--
Phase 3 Trials
1
Priority Reviews
11
Years on Market

Details

Status
Discontinued
First Approved
2015-02-23
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: PANOBINOSTAT LACTATE

FARYDAK Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2015 to 2016
Jun 2016 SUPPL
Label · Labeling
Feb 2015 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What FARYDAK Treats

1 FDA approvals

Originally approved for its first indication in 2015 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT04956302 OSU-21005 NCI-2021-04261 Ph 1 terminated Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT02720510 PANORAMA4 results posted CLBH589DUS106 Ph 2 terminated A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FARYDAK FDA Label Details

View full patent landscape →
2 OB patents · 2 families · 76 international docs across 37 countries

FARYDAK Patents & Exclusivity

Latest Patent: Jun 2028

Patents (2 active)

US8883842 Expires Jun 13, 2028
US7989494 Expires Jan 17, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for FARYDAK

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2028
  • 18 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.